High-dose chemotherapy (HDC) followed by an autologous peripheral blood stem cell transplant (ASCT) provides the best option for long-term survival for patients with relapsed or high-risk lymphoma and prolongs survival in patients with multiple myeloma (MM).
1,2 HDC causes severe anemia and thrombocytopenia, routinely treated with platelet and RBC transfusions. Because for religious reasons Jehovah's Witnesses (JWs) refuse blood transfusions, which they define as RBCs, platelets and plasma, treating these patients has been a unique challenge for physicians. We present an overview of 70 JWs treated with our transfusion-free ASCT protocol, followed by a case study of a JW with MM who received a second transplant upon progression of disease; this procedure had never been performed on a JW due to expected profound pancytopenia.
The Center for Bloodless Medicine and Surgery at Pennsylvania Hospital has treated 70 patients with HDC and ASCT without the use of blood transfusions for lymphoma (39), MM (29) and breast cancer (2) . Although JW do not accept blood transfusions, the decision to accept blood fractions is up to the individual congregant. Most JW will accept PBSCs, albumin, cryoprecipitate, clotting factors and other proteins found in blood. To avoid fresh frozen plasma during cryopreservation, we cryopreserved the patients' stem cells in albumin and normal saline. For our 70 patients, the average age was 47 years (with a range of 21-70 years) and 42 of 70 patients (60%) had over 4.0 Â 10 6 CD34 þ cells per kg reinfused, with an average of 6.0 Â 10 6 CD34 þ cells per kg reinfused (range 0.52-24.6 Â 10 6 CD34 þ cells per kg). Only 14 of 70 (20%) of our patients with lymphoma and MM received a transplant as first-line therapy. Ninety-five percent of our patients with lymphoma had multiple salvage chemotherapy treatments, which may contribute to a poorer graft quality and more significant pancytopenia.
The four most important changes in a transfusion-free transplant include (1) the use of normal saline and albumin in cryopreservation, as mentioned; (2) avoidance of iatrogenic blood loss by minimizing phlebotomy; (3) preparing for a decline in Hb by priming with epoetin alfa and iron and potentially delaying admission after collection to allow for Hb recovery and (4) the prophylactic use of hemostatic agents during the period of profound thrombocytopenia. For our 70 patients, the average drop in Hb was 5.56 g/100 ml (range of 2-10.2 g/100 ml) with an average nadir of 6.4 g/100 ml (range 2-11.6 g/100 ml), which emphasizes the importance of priming to a target Hb above 12 g/100 ml pre-transplant. The platelet count was under 10 Â 10 3 /ml for an average of 4.49 days (range 0-14 days) with 10 patients experiencing a platelet count under 10 Â 10 3 /ml for over 7 days. Thrombocytopenia was managed with IL-11, aminocaproic acid (Amicar), vitamin K and cryoprecipitate. These strategies are applicable to all stem cell transplants and could be used for a wider range of patients. The 100-day mortality at our center is 7 of 70 patients (10.0%) compared with the national mortality rate of 2-4%. 3, 4 Three deaths (4.3%) were due to refusal of blood transfusions, three (4.3%) due to disease progression and one (1.4%) due to pneumonia.
To the best of our knowledge, a second transplant has never been performed on a JW. Because of a JW's refusal of blood products, it was uncertain whether a patient could survive the prolonged duration and degree of pancytopenia that accompanies a second ASCT, where the quality of the graft is reduced with disease relapse and prior treatments.
Here, we report a JW who has received a successful second ASCT. In 1996, a 47-year-old Hispanic man was diagnosed with stage III IgG kappa MM and was treated with vincristine, Adriamycin (doxorubicin) and dexamethasone (VAD) chemotherapy followed by high-dose busulfan and cytoxan with an ASCT. The patient's MM progressed twice and he was treated first with thalidomide then velcade and decadron. The physician recommended a second ASCT because of the durable 7-year remission achieved after the first ASCT, but upon discovering that the patient had converted to a JW and no longer accepted blood transfusions, he was referred to the Center for Bloodless Medicine and Surgery at Pennsylvania Hospital.
In January 2008, the patient began our transfusion-free stem cell transplant protocol (Figure 1 ). Before transplant, the patient was treated with epoetin alfa and sodium ferric gluconate to target a Hb above 12 g/100 ml. G-CSF mobilization and two large volume apheresis collections yielded a total of 5.33 Â 10 6 /kg CD34 þ stem cells. Baseline Hb was 12.7 g/100 ml with a platelet count of 136 Â 10 3 cells per ml. The patient was administered high-dose melphalan at 140 mg/m 2 followed by stem cell rescue. Post transplant he was given epoetin alfa and IL-11. When the platelet count fell below 30 Â 10 3 /ml, patient was treated as defined in our bloodless protocol (see Figure 1) . He experienced profound pancytopenia with a Hb nadir of 5.0 g/100 ml on day 12 and a platelet nadir of 2.0 Â 10 3 /ml on day 9. The Hb was under 8.0 g/100 ml for 16 days, platelets under 10 Â 10 3 /ml for 10 days and ANC under 10 3 cells per ml for 13 days. Post transplant complications included noninfectious diarrhea and non-infectious neutropenic fever with no episodes of bleeding or cardiac compromise.
Our series of transfusion-free ASCT confirms that ASCT should be a treatment option for JWs who refuse blood transfusions. Although there is an increased risk of morbidity and mortality, patients should be offered this treatment with a discussion on the potential risks and benefits. In addition, our case describing a second transplant is evidence that a JW can survive a second transplant and may offer JWs with hematologic malignancies the opportunity to undergo a tandem or second autologous transplant. Letter to the Editor
